TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01313234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Theory based education and systematic daily assessment
Study: NCT02787356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDS Lidocaine 5%; generic
Description: TDS Lidocaine 5%; generic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDS Lidocaine 5%; RLD
Description: TDS Lidocaine 5%; RLD
Study: NCT03176810

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT
Description: OCT is used to guide PCI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: Angiography is used to guide PCI.
Study: NCT02694991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
Study: NCT03853707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipatasertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03509701

Intervention type: DIAGNOSTIC_TEST
Intervention: VZV-specific antibody response from blood
Description: Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva

Intervention type: DIAGNOSTIC_TEST
Intervention: VZV-specific antibody response from blood
Description: Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva
Study: NCT01697384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: histrelin acetate
Description: 52 week implant
Study: NCT03111992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Anti-PD1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Anti-PD1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJM112
Description: Anti-IL-17A antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJM112
Description: Anti-IL-17A antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Description: Oral small molecule SMAC-mimetic
Study: NCT04442594

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality session
Description: The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality session
Description: The virtual reality sessions will take place in a quiet setting twice a week in the living or hosting residence. The sessions will be hold over a period of time of 6 weeks.~The virtual environment will change every 3 weeks in order to avoid the phenomenon of habituation.
Study: NCT01516268

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanyl
Description: As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.~As comparator 1cc normal saline is added to bupivacain in control group for Tap block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanyl
Description: As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.~As comparator 1cc normal saline is added to bupivacain in control group for Tap block.
Study: NCT03572491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: Allantoic split inactivated seasonal influenza vaccine
Study: NCT02722694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous(SC) Abatacept
Description: Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received weekly SC placebo injections for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: All Subjects received backup Methotrexate treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: All Subjects received backup Methotrexate treatment.
Study: NCT03057626

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and urine

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03722017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deprescribing intervention
Description: In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring.
Study: NCT04221295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: Previously described in the arm/group descriptions.
Study: NCT01885442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-bed leg cycle ergometry
Description: Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
Study: NCT01304888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash + nutrition education
Description: Cash transfer of 150 Mexican pesos (equivalent to approximately 14 USD at the time) per month. The size of the cash transfer and the amount of food was the same for all households, i.e. no adjustments for family size or composition were made. Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food basket + nutrition education
Description: Monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food basket w/o nutrition education
Description: A monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were not required to attend nutrition and health education sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No benefits were provided
Study: NCT04677920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Linoleic Acid Healthy Cookies
Description: High Linoleic Acid Healthy Cookies (containing about 10g of grapeseed oil) 1 per day for 2 weeks
Study: NCT03236844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).
Study: NCT02782650

Intervention type: OTHER
Intervention: survey and interview
Description: all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: focus group interviews to further perform in-depth exploration of prenatal counseling preferences
Study: NCT01157481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus nifedipine
Description: Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy
Study: NCT03730935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance training
Description: Respiratory muscle endurance training performed over the duration of 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Respiratory muscle endurance training
Description: Respiratory muscle endurance training performed over the duration of 4 weeks
Study: NCT02402010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjunctive Yoga

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Treatment as Usual
Study: NCT02213276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous Glucose Tolerance Test (IVGTT)
Description: In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
Study: NCT02086435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal morcellation
Description: patients treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracorporeal morcellation
Description: patients treated with standard intracorporeal morcellation, using reusable electronic device
Study: NCT03823859

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry
Description: Resting energy expenditure

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry
Description: Resting energy expenditure

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual energy X-ray Absorptiometry (DXA)
Description: Body composition

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual energy X-ray Absorptiometry (DXA)
Description: Body composition

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: fT4, fT3, TSH, HDL, LDL, triglycerides, cholesterol, HbA1c, Glucose Thyroid panel

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: fT4, fT3, TSH, HDL, LDL, triglycerides, cholesterol, HbA1c, Glucose Thyroid panel
Study: NCT03857308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: This stress reduction training will last 14 days and teach participants skills in concentration, monitoring of present-moment bodily experience, and acceptance of experience. Participants are encouraged to mentally welcome all physical and emotional experience. Each day will consist of approximately 25 to 30 minutes of training.~A full explanation of the mindfulness training compared to the reappraisal training could interfere with study blinding procedures. A complete description can be provided after data collection is complete.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reappraisal Training
Description: This stress reduction training will last 14-days. Each day consists of 25 to 30 minutes of daily practice in Coping control. Participants are encouraged to reframe and reappraise life events, both past and present, and encouraged to solve personal problems through active change.~A full explanation of the reappraisal stress reduction program compared to the mindfulness program could interfere with study blinding procedures. A complete description can be provided after data collection is complete.
Study: NCT01950325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB060-00-AB
Description: VRC01 Human Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB060-00-AB
Description: VRC01 Human Monoclonal Antibody
Study: NCT01777997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
Description: Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment.
Study: NCT01322204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine
Description: One single oral dose of 1 mg/kg of codeine
Study: NCT00773175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human hyaluronidase
Description: 150 Units in 1 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human hyaluronidase
Description: 150 Units in 1 mL
Study: NCT04016324

Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim Basic Evaluation lead and foramen needle
Description: Commercial devices within their intended use as described in approved Instructions for Use.
Study: NCT01950325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB060-00-AB
Description: VRC01 Human Monoclonal Antibody
Study: NCT02908997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MindMate
Description: A dementia-specific mobile reminding application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MindMate
Description: A dementia-specific mobile reminding application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MindMate
Description: A dementia-specific mobile reminding application
Study: NCT02506114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC V/F
Description: PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC V/F
Description: PROSTVAC-V/F is a prostate-specific antigen(PSA)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT01401491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clozapine plus fluvoxamine
Description: clozapine 100 mg/day plus fluvoxamine 50 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clozapine plus placebo
Description: clozapine 300 mg/day plus placebo
Study: NCT04147013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
Study: NCT01621399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 55394
Description: Product 55394 vaginal gel in a prefilled applicator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle (non-treatment)
Description: The vehicle vaginal gel in an applicator (placebo).
Study: NCT01878604

Intervention type: GENETIC
Intervention: Gene analysis
Description: Gene analysis

Intervention type: OTHER
Intervention: Historical data of lipid-lowering drug administration
Description: Collecting historical data of lipid-lowering drug administration
Study: NCT01878604

Intervention type: OTHER
Intervention: Historical data of plasma lipids, xanthoma changes
Description: Collecting historical data of plasma lipids and xanthoma changes
Study: NCT04263818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for
Description: Carrying out the endoscopic procedure planned for the patient with the dedicated colonoscope which has magnetic coils over the entire length of the insertion tube. These magnetic coils generate a pulsed magnetic field at low frequency. These pulses are transmitted to an external receiver, refreshed at 15 images per second, then relayed to the processor to generate a 3D representation of the colonoscope next to it of the endoscopic image. There is no additional risk to the patient compared to current practice.~Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for.
Study: NCT01647867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Met analysis on tissue and blood
Description: 10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
Study: NCT00333229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT04915781

Intervention type: OTHER
Intervention: Not applicable, this is an observational study
Description: Not applicable, this is an observational study
Study: NCT01907633

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
Study: NCT04173338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.
Study: NCT01341184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin 300 mg orally on days 20-41

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 600 mg orally on days 20-41

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: TMC207 400 mg orally on days 1 and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: TMC207 400 mg orally on days 1 and 29